Skip to main content
. 2013 May 13;110(22):8882–8887. doi: 10.1073/pnas.1307237110

Fig. 4.

Fig. 4.

Differential impact of Ras and Akt on sensitivity to SCD1 inhibition. (A) CAY10566 (200 nM) [SCD1 inhibitor (SCDi)] blocks C18:1 labeling from [U-13C]glucose and [U-13C]glutamine. (B and C) Impact of SCDi on A549, iBMK–H-RasV12G, and iBMK-myrAkt cell growth in xCELLigence instrument. CTL is vehicle control. (D) Growth of allografted iBMK–H-RasV12G and iBMK-myrAkt tumors treated with vehicle (CTL) or SCDi (CAY10566, 2.5 mg/kg orally twice daily). (E) Percentage of growth of iBMK–H-RasV12G and iBMK-myrAkt tumors relative to untreated controls, after 13 and 14 d treatment with SCDi, respectively. For A–C, data are means ± SD of n ≥ 3. For D and E, data are means ± SEM of n = 10 mice per group. *P < 0.05; **P < 0.01 (two-tailed t test).